Barclays Maintains Overweight on IDEXX Laboratories, Raises Price Target to $655
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on IDEXX Laboratories (IDXX) and raises the price target from $605 to $655.
February 06, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on IDEXX Laboratories and increases the price target from $605 to $655.
The upgrade in price target by Barclays, a major financial institution, suggests a positive outlook on IDEXX Laboratories' stock. This is likely to instill confidence among investors, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100